Stopping long-acting inhalers for chronic obstructive pulmonary disease (COPD) can lead to a sharp rise in flare-ups for ...

GSK plc GSK announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for ...

The primary finding from the clinical trials for the COPD biologics is reduced annual exacerbations by 30% (BOREAS trial) and 34% (NOTUS trial). In the BOREAS trial, in addition to reduced ...

This publication aims to improve treatment and care for adults with chronic obstructive pulmonary disease (COPD). It provides commissioners with strategies and recommendations for frontline care, ...

Some healthy habits can help reduce your chances of getting lung infections while living with COPD. Learn more here.

When appropriate, surgery remains the most effective treatment option for non-small cell lung cancer (NSCLC), including for patients with COPD, said Friedberg, professor in the Department of Thoracic ...

GSK (GSK) stock is in focus as the company wins EU approval to expand its Nucala asthma drug into chronic obstructive ...

Australia: A new study has found that among people with chronic obstructive pulmonary disease (COPD), beta-blocker therapy ...

GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease: London, UK Saturday, February 7, 2026, 09:00 Hrs [IST] GSK plc announced the E ...

Do vitamin K antagonists affect COPD outcomes? New cohort data explore exacerbation and mortality risk compared with DOACs.

Novel, experimental treatment for emphysema may offer promising results for patients looking to breathe easier ...

Managing mucus from COPD involves strategies that can help loosen mucus and clear it from your airway, such as staying ...